Navigation Links
Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:10/2/2009

demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the SPA agreement on a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. sec
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 WuXi PharmaTech ... open-access R&D capability and technology platform company serving ... announced today that an Investigational New Drug (IND) ... for rheumatoid arthritis has been accepted for review ... In September 2012, MedImmune, the ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... 2015 The Market Element LLC, a ... alliance with Designing Gig LLC to provide website design, ... , “Forging this alliance with Designing Gig represents a ... extend a comprehensive, end-to-end, digital solution for our clients, ... said Chuck Miller, president of The Market Element. “For ...
(Date:3/26/2015)... Neogen Corporation (NASDAQ: NEOG ) announced ... of fiscal 2015, which ended Feb. 28, increased 13% ... Earnings per share in the current quarter were $0.20, ... income increased 17% over prior year to $24,142,000, or ... share, for the same period a year ago. ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... ORLANDO, Fla. , June 26, 2010 ... Eli Lilly and Company (NYSE: LLY ) ... more than 260,000 patients that showed the risk of ... not increased compared to initiators of other antidiabetic therapies. ...
... we will use our mobile phone to buy bus and ... other European states by just presenting an electronic card or ... Most of us hate standing in queues or filling ... signatures could save hours of our time running to offices ...
... NEW YORK , June 25 /PRNewswire-Asia-FirstCall/ -- ... an international biopharmaceutical,company with operations in the U.S. and ... agreements with certain accredited,investors (the "Investors") to sell in a ... of $5 million . Each unit was,priced at ...
Cached Biology Technology:Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 3Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 4Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 5Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 6Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 7Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 8Really smart card project scoops EUREKA 2010 Innovation Award 2Really smart card project scoops EUREKA 2010 Innovation Award 3Really smart card project scoops EUREKA 2010 Innovation Award 4NeoStem Raises $5 Million in Registered Direct Offering 2NeoStem Raises $5 Million in Registered Direct Offering 3NeoStem Raises $5 Million in Registered Direct Offering 4
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... from the Gulf of Mexico following the Deepwater Horizon oil ... (TIEHH) at Texas Tech University have reported that only 8 ... duck eggs resulted in a 50 percent mortality rate. ... remained at sea and exposed to weather had a significant ...
... study focusing on the Central American river turtle ( ... a team of Smithsonian scientists involved in the conservation ... from 238 wild turtles at 15 different locations across ... a "surprising lack" of genetic structure, the scientists write ...
... researchers have published a step by step plan to one-day ... by developing plants that produce their own fertilizer. ... energy required to produce nitrogen fertilizers has pushed the world-wide ... Good says that while they are necessary for high yields, ...
Cached Biology News:Deepwater Horizon crude less toxic to bird eggs after weathering at sea 2Endangered river turtle's genes reveal ancient influence of Maya Indians 2
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
Functionally tested for consistent G-banding of chromosomes....
... Medium is optimized for serum-free growth of ... this protein-free medium, Sf9 cultures routinely reach ... with viabilities above 95%. This medium is ... from X-gluc staining of pBACgus recombinants develops ...
... Grace's Insect Medium is formuatled for ... including Sf9 and Sf21 cells. Grace's ... transfectioin because it does not contain ... interfere with transfection. Grace's Insect Medium, ...
Biology Products: